Actigen

Actigen is a South Korean biotechnology company specializing in the development of next-generation treatments for lysosomal storage disorders (LSDs) and other rare genetic diseases. The company leverages its proprietary ACT-Platform (Advanced Chimeric Technology) to create long-acting recombinant enzymes and gene therapy candidates with improved therapeutic profiles. Its lead programs, AGP101 and AGP102, are designed to treat Pompe disease and Fabry disease, respectively, by enhancing enzyme stability and cellular delivery. Beyond its core focus on LSDs, Actigen is exploring the application of its protein engineering expertise to other metabolic and genetic conditions. The company aims to address significant unmet medical needs by providing more effective and less frequent dosing options compared to current enzyme replacement therapies.